Advertisement

Topics

Doxycycline Hyclate Tablets USP20 mgRx only | Doxycycline Hyclate

04:41 EDT 27th August 2014 | BioPortfolio
Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Doxycycline Hyclate Tablet is available as a 20 mg tablet formulation of doxycycline for oral administration. The structural formula of doxycycline hyclate is:

with an empirical formula of (CHNO•HCl)•CHO•HO and a molecular weight of 1025.89. The chemical designation for doxycycline is 4-(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1, 11-dioxo-2- naphthacenecarboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate.

Doxycycline hyclate is a yellow to light-yellow crystalline powder which is soluble in water.

In addition it also contains the following inactive ingredients; hypromellose, anhydrous lactose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80 and titanium dioxide.

Meets USP Dissolution Test 2

IMAGE doxycycline-hyclate-tablets-1.jpg

After oral administration, doxycycline hyclate is rapidly and nearly completely absorbed from the gastrointestinal tract. Doxycycline is eliminated with a half-life of approximately 18 hours by renal and fecal excretion of unchanged drug.

Doxycycline has been shown to inhibit collagenase activity in vitro..Additional studies have shown that doxycycline reduces the elevated collagenase activity in the gingival crevicular fluid of patients with adult periodontitis.,.The clinical significance of these findings is not known.

Doxycycline is a member of the tetracycline class of antibiotics. The dosage of doxycycline achieved with this product during administration is well below the concentration required to inhibit microorganisms commonly associated with adult periodontitis. Clinical studies with this product demonstrated no effect on total anaerobic and facultative bacteria in plaque samples from patients administered this dose regimen for 9 to 18 months. This product should not be used for reducing the numbers of or eliminating those microorganisms associated with periodontitis.

The pharmacokinetics of doxycycline following oral administration of Doxycycline Hyclate Tablets, USP were investigated in 4 volunteer studies involving 107 adults. Additionally, Doxycycline pharmacokinetics have been characterized in numerous scientific publications. Pharmacokinetic parameters for Doxycycline Hyclate Tablets following single oral doses and at steady-state in healthy subjects are presented as follows:

Pharmacokinetic Parameters for Doxycycline Hyclate Tablets
   n  Cmax *
(ng/mL)
 Tmax **
(hr)
 Cl/F*
(L/hr)
 t1/2 *
(hr)
 Single dose 20 mg
(tablet)
 20  362 ± 101  1.4
(1-2.5)
 3.85 ± 1.3  18.1 ± 4.85
 Steady-State
20 mg BID***
 30  790 ± 285  2
(0.98-12)
 3.76 ± 1.06  Not
Determined

Doxycycline is well absorbed after oral administration. In a single-dose study, concomitant administration of Doxycycline Hyclate Tablets, USP with a 1000 calorie, high-fat, high-protein meal which included dairy products, in healthy volunteers, resulted in a decrease in the rate and extent of absorption and delay in the time to maximum concentrations.

Doxycycline is greater than 90% bound to plasma proteins. Its apparent volume of distribution is variously reported as between 52.6 and 134 L.

Major metabolites of doxycycline have not been identified. However, enzyme inducers such as barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.

Doxycycline is excreted in the urine and feces as unchanged drug. It is variously reported that between 29% and 55.4% of an administered dose can be accounted for in the urine by 72 hours. Half-life averaged 18 hours in subjects receiving a single 20 mg doxycycline dose.

Doxycycline pharmacokinetics have not been evaluated in geriatric patients.

Doxycycline pharmacokinetics have not been evaluated in pediatric patients (See  WARNINGS  section).

Doxycycline pharmacokinetics were compared in 9 men and 11 women under fed and fasted conditions. While female subjects had a higher rate (C) and extent of absorption (AUC), these differences are thought to be due to differences in body weight/lean body mass. Differences in other pharmacokinetic parameters were not significant.

Differences in doxycycline pharmacokinetics among racial groups have not been evaluated.

Studies have shown no significant difference in serum half-life of doxycycline in patients with normal and severely impaired renal function. Hemodialysis does not alter the half-life of doxycycline.

Doxycycline pharmacokinetics have not been evaluated in patients with hepatic insufficiency.

(See PRECAUTIONS section)

In a randomized, multi-centered, double-blind, 9-month Phase 3 study involving 190 adult patients with periodontal disease [at least two probing sites per quadrant of between 5 and 9 mm pocket depth (PD) and level (ALv)], the effects of oral administration of 20 mg twice a day of doxycycline hyclate (using a bioequivalent capsule formulation) plus scaling and root planing (SRP) were compared to placebo control plus SRP. Both treatment groups were administered a course of scaling and root planing in 2 quadrants at Baseline. Measurements of ALv, PD and bleeding-on-probing (BOP) were obtained at Baseline, 3, 6, and 9 months from each site about each tooth in the two quadrants that received SRP using the UNC-15 manual probe. Each tooth site was categorized into one of three strata based on Baseline PD: 0 to 3 mm (no disease), 4 to 6 mm (mild/moderate disease), ≥ 7 mm (severe disease). For each stratum and treatment group, the following were calculated at month 3, 6, and 9; mean change in ALv from baseline, mean change in PD from baseline, mean percentage of tooth sites per patient exhibiting attachment loss of ≥ 2 mm from baseline, and percentage of tooth sites with bleeding on probing. The results are summarized in the following table.

*p<0.050 vs. the placebo control group                      **p<0.010 vs. the placebo control group†ALv = Clinical Attachment Level                                  †† PD = Pocket Depth ff SD = Standard Deviation                                            f BOP = Bleeding on Probing 

Clinical Results at Nine Months of Doxycycline Hyclate Capsules 20 mg, as an Adjunct to SRP (Bioequivalent to Doxycycline Hyclate Tablets, 20 mg)    Parameter                                                                          Baseline Pocket Depth
0 to 3 mm  4 to 6 mm  ≥ 7 mm 
 Number of Patients      
(Doxycycline hyclate tablets 20 mg BID)  90   90  79
 Number of Patients      
 (Placebo)  93  93  78
 Mean Gain (SD ff ) in ALv      
 Doxycycline hyclate tablets 20 mg BID  0.25 (0.29)mm  1.03 (0.47)mm*  1.55 (1.16)mm*
 Placebo  0.20 (0.29)mm  0.86 (0.48)mm  1.17 (1.15)mm
 Mean Decrease (SD ff ) in PD††      
 Doxycycline hyclate tablets 20 mg BID  0.16 (0.19)mm**  0.95 (0.47)mm**  1.68 (1.07)mm**
 Placebo  0.05 (0.19)mm  0.69 (0.48)mm  1.20 (1.06)mm
 % of Sites (SD ff ) with loss of ALv ≥2mm      
 Doxycycline hyclate tablets 20 mg BID  1.9 (4.2)%  1.3 (4.5)%  0.3 (9.4)%*
 Placebo  2.2 (4.1)%  2.4 (4.4)%  3.6 (9.4)%
 % of Sites (SD ff) with BOPf      
 Doxycycline hyclate tablets 20 mg BID  39 (19)% **  64 (18)%*  75 (29)%
 Placebo  46 (19)%  70 (18)%  80 (29)%

Doxycycline Hyclate Tablets, USP  are indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis.

This drug is contraindicated in persons who have shown hypersensitivity to doxycycline or any of the other tetracyclines.

THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN). This adverse reaction is more common during long-term use of the drugs but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP AND IN PREGNANT OR NURSING MOTHERS UNLESS THE POTENTIAL BENEFITS MAY BE ACCEPTABLE DESPITE THE POTENTIAL RISKS.

All tetracyclines form a stable calcium complex in any bone forming tissue. A decrease in fibula growth rate has been observed in premature infants given oral tetracyclines in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued.

Doxycycline can cause fetal harm when administered to a pregnant woman. Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development).

Evidence of embryotoxicity has also been noted in animals treated early in pregnancy. If any tetracyclines are used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

The catabolic action of the tetracyclines may cause and increase in BUN. Previous studies have not observed an increase in BUN with the use of doxycycline in patients with impaired renal function.

Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.

While no overgrowth by opportunistic microorganisms such as yeast were noted during clinical studies, as with other antimicrobials, Doxycycline Hyclate Tablets, USP therapy may result in overgrowth of nonsusceptible microorganisms including fungi.

The use of tetracyclines may increase the incidence of vaginal candidiasis.

Doxycycline Hyclate Tablets, USP should be used with caution in patients with a history or predisposition to oral candidiasis. The safety and effectiveness of Doxycycline Hyclate Tablets, USP  has not been established for the treatment of periodontitis in patients with coexistent oral candidiasis.

If superinfection is suspected, appropriate measures should be taken.

In long term therapy, periodic laboratory evaluations of organ systems, including hematopoietic, renal, and hepatic studies should be performed.

Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

Since bacterial antibiotics, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of members of the β-lactam (e.g. penicillin) class of antibiotics, it is not advisable to administer these antibiotics concomitantly.

Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations, and by bismuth subsalicylate.

Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.

The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.

Concurrent use of tetracyclines may render oral contraceptives less effective.

False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.

Doxycycline hyclate was assessed for potential to induce carcinogenesis in a study in which the compound was administered to Sprague-Dawley rats by gavage at dosages of 20, 75, and 200 mg/kg/day for two years. An increased incidence of uterine polyps was observed in female rats that received 200 mg/kg/day, a dosage that resulted in a systemic exposure to doxycycline approximately nine times that observed in female humans that used doxycycline hyclate tablets (exposure comparison based upon AUC values). No impact upon tumor incidence was observed in male rats at 200 mg/kg/day, or in either gender at the other dosages studied. Evidence of oncogenic activity was obtained in studies with related compounds, i.e., oxytetracycline (adrenal and pituitary tumors), and minocycline (thyroid tumors).

Doxycycline hyclate demonstrated no potential to cause genetic toxicity in an in vitro point mutation study with mammalian cells (CHO/HGPRT forward mutation assay) or in an in vivo micronucleus assay conducted in CD-1 mice. However, data from an in vitro assay with CHO cells for potential to cause chromosomal aberrations suggest that doxycycline hyclate is a weak clastogen.

Oral administration of doxycycline hyclate to male and female Sprague-Dawley rats adversely affected fertility and reproductive performance, as evidenced by increased time for mating to occur, reduced sperm motility, velocity, and concentration, abnormal sperm morphology, and increased pre-and post-implantation losses. Doxycycline hyclate induced reproductive toxicity at all dosages that were examined in this study, as even the lowest dosage tested (50 mg/kg/day) induced a statistically significant reduction in sperm velocity. Note that 50 mg/kg/day is approximately 10 times the amount of doxycycline hyclate contained in the recommended daily dose of Doxycycline Hyclate Tablets, USP for a 60 kg human when compared on the basis of body surface area estimates (mg/m). Although doxycycline impairs the fertility of rats when administered at sufficient dosage, the effect of doxycycline hyclate on human fertility is unknown.

 Pregnancy Category D. (See  WARNINGS   Section). Results from animal studies indicate that doxycycline crosses the placenta and is found in fetal tissues.

(See  WARNINGS   Section).

The effect of tetracyclines on labor and delivery is unknown.

Tetracyclines are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from doxycycline, the use of Doxycycline Hyclate Tablets, USP in nursing mothers is contraindicated. (See  WARNINGS   Section).

The use of Doxycycline Hyclate Tablets, USP  in infancy and childhood is contraindicated. (See  WARNINGS   section.)

In clinical trials of adult patients with periodontal disease 213 patients received 20 mg BID over a 9 to 12 month period. The most frequent adverse reactions occurring in studies involving treatment with a bioequivalent form of doxycycline hyclate capsules or placebo are listed below:

 Incidence (%) of Adverse Reactions in Clinical Trials of
Doxycycline Hyclate Capsules, 20 mg
(Bioequivalent to Doxycycline Hyclate Tablets, 20 mg) vs. Placebo
 Adverse Reactions  Doxycycline
Hyclate Capsules
20 mg BID
(n=213)
 Placebo
(n=215)
 Headache  55 (26%)  56 (26%)
 Common Cold  47 (22%)  46 (21%)
 Flu Symptoms  24 (11%)  40 (19%)
 Tooth Ache  14 (7%)  28 (13%)
 Periodontal Abscess  8 (4%)  21 (10%)
 Tooth Disorder  13 (6%)  19 (9%)
 Nausea  17 (8%)  12 (6%)
 Sinusitis  7 (3%)  18 (8%)
 Injury  11 (5%)  18 (8%)
 Dyspepsia  13 (6%)  5 (2%)
 Sore Throat  11 (5%)  13 (6%)
 Joint Pain  12 (6%)  8 (4%)
 Diarrhea  12 (6%)  8 (4%)
 Sinus Congestion  11 (5%)  11 (5%)
 Coughing  9 (4%)  11 (5%)
 Sinus Headache  8 (4%)  8 (4%)
 Rash  8 (4%)  6 (3%)
 Back Pain  7 (3%)  8 (4%)
 Back Ache  4 (2%)  9 (4%)
 Menstrual Cramp  9 (4%)  5 (2%)
 Acid Indigestion  8 (4%)  7 (3%)
 Pain  8 (4%)  5 (2%)
 Infection  4 (2%)  6 (3%)
 Gum Pain  1 (<1%)  6 (3%)
 Bronchitis  7 (3%)  5 (2%)
 Muscle Pain  2 (1%)  6 (3%)

The following adverse reactions have been observed in patients receiving tetracyclines:

Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inflammatory lesions (with vaginal candidiasis) in the anogenital region. Hepatotoxicity has been reported rarely. Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving the capsule forms of the drugs in the tetracycline class. Most of these patients took medications immediately before going to bed. (See  DOSAGE AND ADMINISTRATION   Section).

Maculopapular and erythematous rashes. Exfoliative dermatitis has been reported but is uncommon. Photosensitivity is discussed above. (See  WARNINGS   Section).

Rise in BUN has been reported and is apparently dose related. (See  WARNINGS   Section).

Urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus.

Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported.

In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdose.

THE DOSAGE OF DOXYCYCLINE HYCLATE TABLETS, USP DIFFERS FROM THAT OF DOXYCYCLINE USED TO TREAT INFECTIONS. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS INCLUDING THE DEVELOPMENT OF RESISTANT MICROORGANISMS.

Doxycycline Hyclate Tablets, USP 20 mg twice daily as an adjunct following scaling and root planing may be administered for up to 9 months. Doxycycline Hyclate Tablets, USP  should be taken twice daily at 12 hour intervals, usually in the morning and evening. It is recommended that if Doxycycline Hyclate Tablets, USP  is taken close to meal times, allow at least one hour prior to or two hours after meals. Safety beyond 12 months and efficacy beyond 9 months have not been established.

Administration of adequate amounts of fluid along with the tablets is recommended to wash down the drug and reduce the risk of esophageal irritation and ulceration. (See  ADVERSE REACTIONS   Section).

Doxycycline Hyclate Tablets,  USP 20 mg are supplied as white, round film coated tablets debossed “cor” over “152” on one side and other side is plain.

They are supplied as follows:Bottles of 100 (NDC 64720-152-10)

Store at 20°C to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Dispense in tight, light-resistant containers as defined in the USP/NF.

Keep this and all drugs out of the reach of children.

LB#  298-01                                                       Rev.  December, 2010 Manufactured byCorPharma, LLCMiddlesex, NJ 08846

1.    Golub L.M., Sorsa T., Lee H-M, Ciancio S., Sorbi D., Ramamurthy N.S., Gruber B., Salo T., Konttinen Y.T.: Doxycycline Inhibits Neutrophil (PMN)-type Matrix Metalloproteinases in Human Adult Periodontitis Gingiva J. Clin. Periodontol 1995; 22: 100-109.

2.  Golub L.M., Ciancio S., Ramamurthy N.S., Leung M., McNamara T.F.: Low-dose Doxycycline Therapy:  Effect on Gingival and Crevicular Fluid Collagenase Activity in Humans.  J. Periodont Res 1990; 25: 321-330.

3.  Golub L.M., Lee H.M., Greenwald R.A., Ryan M.E., Salo T., Giannobile W.V.: A Matrix Metalloproteinase Inhibitor Reduces Bone-type Collagen Degradation Fragments and Specific Collegenases in Gingival Crevicular Fluid During Adult Periodontitis, Inflammation Research 1997; 46: 310-319.

4,    Saivain S., Houin G.: Clinical Pharmacokinetics of Doxycycline and Minocycline. Clin. Pharmacokinetics 1988; 15; 355-366.

5.    Schach von Wittenau M., Twomey T.: The Disposition of Doxycycline by Man and Dog. Chemotherapy 1971; 16: 217-228.

6.    Campistron G., Coulais Y., Caillard C., Mosser J., Pontagnier H., Houin G.: Pharmacokinetics and Bioavailability of Doxycycline in Humans. Arzneimittel Forschung 1986; 36: 1705-1707.

IMAGE doxycycline-hyclate-tablets-2.jpg

Manufacturer

Corepharma LLC.

Active Ingredients

Source

Drugs and Medications [85 Associated Drugs and Medications listed on BioPortfolio]

Doxycycline hyclate [Global Pharmaceuticals, Division of Impax Laboratories Inc.]

These highlights do not include all the information needed to use doxycycline hyclate delayed-release tablets, USP safely and effectively. See Full Prescribing Information for doxycycline hyclate dela...

Doxycycline hyclate [IVAX Pharmaceuticals, Inc.]

DOXYCYCLINE HYCLATE TABLETS USPRx only

Doxycycline hyclate [Mutual Pharmaceutical Company, Inc.]

DOXYCYCLINE HYCLATETABLETS USP

Doxycycline hyclate [Larken Laboratories, Inc.]

DOXYCYCLINE HYCLATE TABLETS, USP

Doxycycline hyclate [Sandoz Inc]

Doxycycline Hyclate Tablets USP20 mgRx only

Clinical Trials [120 Associated Clinical Trials listed on BioPortfolio]

Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate

Randomized, multi-center, open label, active-comparator study to compare the efficacy and tolerability of Doryx Delayed Release Tablets to doxycycline hyclate in patients with moderate to ...

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris

The purpose of this study is to demonstrate the efficacy of Adapalene 0.1% / Benzoyl Peroxide (quoted as BPO) 2.5% Gel associated with Doxycycline Hyclate 100 mg Tablets compared to Adapal...

Effects of Low-Dose Doxycycline on Oral Bone Loss

The primary purpose of this clinical trial is to determine whether low-dose doxycycline can reduce alveolar bone density loss in postmenopausal osteopenic women with periodontitis and not ...

Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens

To compare the safety and efficacy of two treatment regimens: 1) COL-101 and metronidazole gel 1%; 2) Doxycycline hyclate 100 mg and metronidazole gel 1%

A Treatment for Severe Inflammatory Acne Subjects

Demonstrate that a daily treatment regimen of adapalene 0.3%/benzoyl peroxide 2.5% gel + oral Doxycycline 200 mg is effective and safe in severe inflammatory acne with 3 or fewer nodules o...

PubMed Articles [93 Associated PubMed Articles listed on BioPortfolio]

Influence of Market Competition on Tetracycline Pricing and Impact of Price Increases on Clinician Prescribing Behavior.

Oral tetracyclines are commonly used for acne and other conditions. Recent generic price increases threaten access to these medications. Using the OptumInsight™ Clinformatics™ DataMart, we retrosp...

Dental staining after doxycycline use in children.

The use of doxycycline has been avoided before 8 years of age due to known dental staining caused by tetracyclines, although doxycycline differs from classical tetracyclines in many ways. Doxycyclin...

Considerations for using minocycline vs doxycycline for treatment of canine heartworm disease.

Doxycycline has been considered the first drug of choice for treating Wolbachia, a member of the Rickettsiaceae, which has a symbiotic relationship with filarial worms, including heartworms. Wolbachia...

Doxycycline can be given to children without risk of staining of teeth In Sweden, several hundred children are treated for Lyme neuroborreliosis annually, the majority of which are treated with intrav...

Doxycycline in the management of sexually transmitted infections.

Doxycycline is a second-generation tetracycline, available worldwide for half a century. It is an inexpensive broad-spectrum antimicrobial agent largely used in the management of several bacterial inf...

Quick Search
Advertisement
 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record